Sorin is now LivaNova. Learn more here

Sep 01, 2015

SORIN GROUP INITIATES TRIUMPH CRT CLINICAL TRIAL WITH WORLD'S FIRST TRIPLE SITE VENTRICULAR (TRI-V) PACING

The study will evaluate whether response to cardiac resynchronization therapy (CRT) may be improved in selected heart failure patients through Tri-V pacing.

Milan, Italy, September 1st, 2015 – Sorin Group announced today the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.

The TRIUMPH CRT study, which will be conducted using Sorin Group’s Paradym CRT-D Tri-V device, is designed to investigate the benefits of individually optimized Tri-V pacing over standard biventricular pacing in patients with a non-Left Bundle Branch Block (LBBB) morphology.

While standard CRT-D devices deliver ventricular pacing at two different ventricular sites, Paradym CRT-D Tri-V paces the ventricles at three different locations thanks to a special connector that enables the use of three ventricular leads without the need for any separate adaptor. 

“There is a need to find alternative CRT solutions for patients that have a poor response to the standard therapy. The TRIUMPH-CRT trial focuses specifically on non-LBBB heart failure patients, and we want to demonstrate that individually optimized Tri-V pacing will help to significantly improve their ventricular function”, said Professor Jean-Claude Daubert, M.D., Hôpital Pontchaillou, University of Rennes, France, the study’s principal investigator. “In addition, using a specially designed Tri-V device with a dedicated connector will streamline the implant procedure and limit further complications”.

View full text release

Latest News

Version unknown | Revision 102327 | Status unstable | SessionId BA9B090F404CFFE52F27A8BFF7CE5378.jvm0